Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
MSD has begun taking steps towards developing a smaller easier-to-swallow tablet version of its oral COVID-19 therapy Lagevrio (molnupiravir), the company’s Japan development chief Hiromichi Shirasawa said on October 19. Lagevrio is currently available in a large capsule formulation, which…
To read the full story
Related Article
- Lagevrio’s Smaller Tablet Version Filed in Japan: MSD
April 17, 2024
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





